ARTMS Inc. (ARTMS), the global player engaged in developing and commercializing novel products enabling cyclotron production of the world’s most needed medical radioisotopes, announced the submission of a Type 1 Master File with the Health Products & Food Branch, Health Canada (HC) for the production of gallium-68 (Ga-68),  a critical medical isotope of significant clinical importance in nuclear medicine diagnostic procedures utilizing Positron Emission Tomography (PET) imaging. ARTMS’ Health Canada expressed that this will help alleviate the current supply constraints and provide innovators with the ability to advance new radiopharmaceutical drugs into development.

On the basis of the filing, ARTMS has also entered into a tri-party co-operation with fellow industry leaders, POINT Biopharma (NASDAQ: PNT) and the Canadian Molecular Imaging Probe Consortium (CanProbe), a joint venture between the Centre for Probe Development and Commercialization (CPDC) and the University Health Network (UHN)), for the development and clinical use of innovative radiopharmaceuticals in Canada. ARTMS, through the QUANTM Irradiation System ecosystem, provides a pathway for large scale isotope production of Zr-89, Cu-64 and Tc-99m.

To read more please visit:

ARTMS Inc. Announces Health Canada Submission for Ga-68 Production and Tri-party Collaboration to Advance Ga-68 Imaging Products

Source: artms